Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906896 | 0.88 | BRD4 (0.70) | METAP1BRD4CYP1A2MAPTCYP2C19 | |
| SCHEMBL4244032 | 0.85 | BRD4 (0.55) | METAP1BRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2412625 | 0.81 | GPR35 (0.39) | METAP1BRD4CYP1A2MAPTCYP2C19 | |
| SCHEMBL13211408 | 0.80 | METAP1 (0.64) | METAP1BRD4TDP2BRD9NAMPT | |
| SCHEMBL31047027 | 0.80 | METAP1 (0.64) | METAP1BRD4CYP3A4MAPTTDP2 | |
| SCHEMBL30937705 | 0.80 | METAP1 (0.64) | METAP1BRD4TDP2BRD9NAMPT | |
| SCHEMBL4345991 | 0.79 | METAP1 (0.62) | METAP1BRD4TDP2BRD9ALDH1A1 | |
| SCHEMBL7848797 | 0.78 | METAP1 (0.52) | METAP1BRD4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL30668778 | 0.77 | METAP1 (0.56) | METAP1BRD4TDP2BRD9NAMPT | |
| SCHEMBL3243855 | 0.77 | METAP1 (0.56) | METAP1BRD4TDP2BRD9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| CN-110914248-A | LXR modulators containing amines or (thio) amides | 菲尼克斯-FXR股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011119694-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119694-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135464-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | METAP1 919/4885BRD4 423/4885CYP1A2 2068/4885 |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | METAP1 4175/4885BRD4 446/4885CYP1A2 2390/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | METAP1 2110/4885BRD4 551/4885CYP1A2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.